Pay in 4 interest-free payments of $5.74 Learn more
Ships within 48 hours · Estimated delivery Nov 3 - Nov 8
Fifth, cost-effectiveness analyses are critical given the high price of current GLP-1 RAs and the large potential treatment population: preliminary health-economic models suggest acceptable cost-effectiveness ratios in high-fibrosis patients with comorbid type 2 diabetes and cardiovascular disease, but robust data in broader MASLD populations are lacking
The primary goals of treatment are restoration of facial volume, stimulation of collagen production, regenerative enhancement, and management of excess skin
a 330 mcg dose = 0.099 mL = ~10 units
Its generally considered far less uncomfortable than having blood taken
US$ 21.68
US$ 20.20
US$ 27.83
US$ 29.69
US$ 26.09
